Literature DB >> 18196272

Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques.

Yujuan Yue1, Zhongde Wang, Kristina Abel, Jinliang Li, Lisa Strelow, Angelo Mandarino, Meghan K Eberhardt, Kimberli A Schmidt, Don J Diamond, Peter A Barry.   

Abstract

A vaccine consisting of rhesus cytomegalovirus (RhCMV) pp65-2, gB and IE1 expressed via modified vaccinia Ankara (MVA) was evaluated in rhesus macaques with or without prior priming with expression plasmids for the same antigens. Following two MVA treatments, comparable levels of anti-gB, pp65-2 and neutralizing antibody responses, and pp65-2- and IE1-specific cellular immune responses were detected in both vaccinated groups. Similar reductions in plasma peak viral loads were observed in these groups compared to untreated controls. This study demonstrates the immunogenicity and protective efficacy of rMVA-based RhCMV subunit vaccines in a primate host and warrants further investigation to improve the efficacy of subunit vaccines against CMV.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18196272     DOI： 10.1007/s00430-008-0074-5

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN： 0300-8584            Impact factor:   3.402


  26 in total

1.  A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.

Authors:  R F Pass; A M Duliegè; S Boppana; R Sekulovich; S Percell; W Britt; R L Burke
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

2.  Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine.

Authors:  Harriet L Robinson; David C Montefiori; Francois Villinger; James E Robinson; Sunita Sharma; Linda S Wyatt; Patricia L Earl; Harold M McClure; Bernard Moss; Rama Rao Amara
Journal:  Virology       Date:  2006-06-05       Impact factor: 3.616

3.  A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

Authors:  S P Adler; S A Plotkin; E Gonczol; M Cadoz; C Meric; J B Wang; P Dellamonica; A M Best; J Zahradnik; S Pincus; K Berencsi; W I Cox; Z Gyulai
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

4.  Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques.

Authors:  Yujuan Yue; Amitinder Kaur; Meghan K Eberhardt; Nadine Kassis; Shan Shan Zhou; Alice F Tarantal; Peter A Barry
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

5.  Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques.

Authors:  J L Huff; R Eberle; J Capitanio; S S Zhou; P A Barry
Journal:  J Gen Virol       Date:  2003-01       Impact factor: 3.891

6.  Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.

Authors:  Mark R Schleiss; Nigel Bourne; Greg Stroup; Fernando J Bravo; Nancy J Jensen; David I Bernstein
Journal:  J Infect Dis       Date:  2004-04-01       Impact factor: 5.226

7.  Flow cytometric analysis of virus-specific T lymphocytes: practicability of detection of HCMV-specific T lymphocytes in whole blood in patients after stem cell transplantation.

Authors:  Sigune Buxbaum; Frank Bernhard Kraus; Anke Hahn; Olaf Beck; Birgit Kabartas; Hans Wilhelm Doerr; Beatrice Ludwig
Journal:  J Immunol Methods       Date:  2006-02-28       Impact factor: 2.303

8.  Prevention of transfusion-acquired cytomegalovirus infections in newborn infants.

Authors:  A S Yeager; F C Grumet; E B Hafleigh; A M Arvin; J S Bradley; C G Prober
Journal:  J Pediatr       Date:  1981-02       Impact factor: 4.406

9.  A recombinant rhesus cytomegalovirus expressing enhanced green fluorescent protein retains the wild-type phenotype and pathogenicity in fetal macaques.

Authors:  W L William Chang; Alice F Tarantal; Shan Shan Zhou; Alexander D Borowsky; Peter A Barry
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate.

Authors:  E Gönczöl; K Berensci; S Pincus; V Endresz; C Méric; E Paoletti; S A Plotkin
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641
View more
  27 in total

Review 1.  Oncomodulation by human cytomegalovirus: evidence becomes stronger.

Authors:  Martin Michaelis; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Med Microbiol Immunol       Date:  2009-02-07       Impact factor: 3.402

2.  Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.

Authors:  Edwin R Manuel; Zhongde Wang; Zhongqi Li; Corinna La Rosa; Wendi Zhou; Don J Diamond
Journal:  Virology       Date:  2010-05-14       Impact factor: 3.616

3.  Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission.

Authors:  Kristy M Bialas; Takayuki Tanaka; Dollnovan Tran; Valerie Varner; Eduardo Cisneros De La Rosa; Flavia Chiuppesi; Felix Wussow; Lisa Kattenhorn; Sheila Macri; Erika L Kunz; Judy A Estroff; Jennifer Kirchherr; Yujuan Yue; Qihua Fan; Michael Lauck; David H O'Connor; Allison H S Hall; Alvarez Xavier; Don J Diamond; Peter A Barry; Amitinder Kaur; Sallie R Permar
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205

4.  Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.

Authors:  Kristina Abel; Joy Martinez; Yujuan Yue; Simon F Lacey; Zhongde Wang; Lisa Strelow; Anindya Dasgupta; Zhongqi Li; Kimberli A Schmidt; Kristie L Oxford; Basel Assaf; Jeffrey A Longmate; Don J Diamond; Peter A Barry
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

5.  Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.

Authors:  Elizabeth C Swanson; Pete Gillis; Nelmary Hernandez-Alvarado; Claudia Fernández-Alarcón; Megan Schmit; Jason C Zabeli; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2015-06-13       Impact factor: 3.641

Review 6.  Update on the current status of cytomegalovirus vaccines.

Authors:  Heungsup Sung; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2010-11       Impact factor: 5.217

7.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

8.  A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

Authors:  Felix Wussow; Yujuan Yue; Joy Martinez; Jesse D Deere; Jeff Longmate; Andreas Herrmann; Peter A Barry; Don J Diamond
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

9.  A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.

Authors:  Kristina Abel; Lisa Strelow; Yujuan Yue; Meghan K Eberhardt; Kimberli A Schmidt; Peter A Barry
Journal:  Vaccine       Date:  2008-08-27       Impact factor: 3.641

10.  Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.

Authors:  Zhongde Wang; Joy Martinez; Wendi Zhou; Corinna La Rosa; Tumul Srivastava; Anindya Dasgupta; Ravindra Rawal; Zhongqui Li; William J Britt; Don Diamond
Journal:  Vaccine       Date:  2009-12-05       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.